BACKGROUND: Allergic rhinoconjunctivitis (AR/C) is a global health problem causing significant morbidity and has a major impact on quality of life (QOL) and health expenditure. Despite the widespread prevalence, the overall health impact of AR/C may be underappreciated. The results of a survey designed to capture the burden of allergic rhinitis within the Asia-Pacific region have been published recently. Of particular note when evaluating treatment in this region was the fact that despite the value of intranasal corticosteroid (INCS) use, only a small percentage of patients used them. Whether this same trend is present within the population of Australian sufferers is unknown. This study examines the burden of AR/C and explores use of, and attitudes, to INCS sprays in the Australian population. METHODS: Three hundred three completed interviews from adults and children who had physician-diagnosed AR/C and who were symptomatic or had received treatment in the previous 12 months were analyzed for QOL measures and attitudes to INCS use. RESULTS: Most patients surveyed had received their diagnosis from a general practitioner (GP), and in most cases, a GP provided the majority of ongoing medical care. Only 8% of respondents had consulted a relevant specialist. Diagnostic tests had not been performed in 55% of respondents. The major symptoms causing most distress were nasal congestion and ocular symptoms. The burden of AR/C was considerable; 42% described significant work or school interference because of symptoms, one-third reporting moderate-to-extreme interference with sleep. Despite the significant impact on QOL reported by this sample, 17% had never used INCS and 27% had not used them in the previous 12 months. Respondents' knowledge about INCSs was poor. CONCLUSION: AR/C is a common disease associated with significant morbidity and impairment of QOL. Improvement in diagnosis, management, and patient education is needed.
BACKGROUND:Allergic rhinoconjunctivitis (AR/C) is a global health problem causing significant morbidity and has a major impact on quality of life (QOL) and health expenditure. Despite the widespread prevalence, the overall health impact of AR/C may be underappreciated. The results of a survey designed to capture the burden of allergic rhinitis within the Asia-Pacific region have been published recently. Of particular note when evaluating treatment in this region was the fact that despite the value of intranasal corticosteroid (INCS) use, only a small percentage of patients used them. Whether this same trend is present within the population of Australian sufferers is unknown. This study examines the burden of AR/C and explores use of, and attitudes, to INCS sprays in the Australian population. METHODS: Three hundred three completed interviews from adults and children who had physician-diagnosed AR/C and who were symptomatic or had received treatment in the previous 12 months were analyzed for QOL measures and attitudes to INCS use. RESULTS: Most patients surveyed had received their diagnosis from a general practitioner (GP), and in most cases, a GP provided the majority of ongoing medical care. Only 8% of respondents had consulted a relevant specialist. Diagnostic tests had not been performed in 55% of respondents. The major symptoms causing most distress were nasal congestion and ocular symptoms. The burden of AR/C was considerable; 42% described significant work or school interference because of symptoms, one-third reporting moderate-to-extreme interference with sleep. Despite the significant impact on QOL reported by this sample, 17% had never used INCS and 27% had not used them in the previous 12 months. Respondents' knowledge about INCSs was poor. CONCLUSION: AR/C is a common disease associated with significant morbidity and impairment of QOL. Improvement in diagnosis, management, and patient education is needed.
Authors: David Price; Christine Bond; Jacques Bouchard; Rui Costa; Joseph Keenan; Mark L Levy; Mari Orru; Dermot Ryan; Samantha Walker; Margaret Watson Journal: Prim Care Respir J Date: 2005-12-27
Authors: Jan L Brozek; Jean Bousquet; Carlos E Baena-Cagnani; Sergio Bonini; G Walter Canonica; Thomas B Casale; Roy Gerth van Wijk; Ken Ohta; Torsten Zuberbier; Holger J Schünemann Journal: J Allergy Clin Immunol Date: 2010-09 Impact factor: 10.793
Authors: Jean Bousquet; Françoise Neukirch; Philippe J Bousquet; Pierre Gehano; Jean Michel Klossek; Martine Le Gal; Bashar Allaf Journal: J Allergy Clin Immunol Date: 2005-12-02 Impact factor: 10.793
Authors: Boris A Stuck; Julia Czajkowski; Anna-Eva Hagner; Ludger Klimek; Thomas Verse; Karl Hörmann; Joachim T Maurer Journal: J Allergy Clin Immunol Date: 2004-04 Impact factor: 10.793
Authors: Michael S Benninger; James A Hadley; J David Osguthorpe; Bradley F Marple; Donald A Leopold; M Jennifer Derebery; Maureen Hannley Journal: Otolaryngol Head Neck Surg Date: 2004-01 Impact factor: 5.591
Authors: Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek Journal: Int Forum Allergy Rhinol Date: 2018-02 Impact factor: 3.858
Authors: Sinthia Bosnic-Anticevich; Peter Smith; Michael Abramson; Charlotte Mary Hespe; Menai Johnson; Rodney Stosic; David B Price Journal: BMJ Open Date: 2020-11-24 Impact factor: 2.692
Authors: Ralph Mösges; Dennis Lip Yen Lee; Jovilia Abong; Bella Siasoco; Steven Kw Chow; Jern-Lin Leong; Harvinder Singh; S Kuljit; Benjamin Campomanes Journal: Asia Pac Allergy Date: 2016-01-27
Authors: David B Price; Pete K Smith; Richard John Harvey; A Simon Carney; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek Skinner; Victoria Carter; Alice Ms Durieux Journal: Pragmat Obs Res Date: 2018-08-15